| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a692001 |
| ATC code | |
| Pharmacokinetic data | |
| Elimination half-life | 3.6–10.4 min |
| Identifiers | |
| |
| CAS Number | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| Chemical and physical data | |
| Formula | C2532H3854N672O711S16 |
| Molar mass | 55597.64 g·mol−1 |
 N Y (what is this?) (verify) | |
Alglucerase was a biopharmaceutical drug for the treatment of Gaucher's disease. It was a modified form of human β-glucocerebrosidase enzyme, where the non-reducing ends of the oligosaccharide chains have been terminated with mannose residues.1
Ceredase is the trade name of a citrate buffered solution of alglucerase that was manufactured by Genzyme Corporation from human placental tissue.1 It is given intravenously in the treatment of Type 1 Gaucher's disease. This was the first drug approved as an enzyme replacement therapy.1
It was approved by the FDA in 1991.2 It has been withdrawn from the market34 due to the approval of similar drugs made with recombinant DNA technology instead of being harvested from tissue; drugs made recombinantly, since there is no concern about diseases being transmitted from the tissue used in harvesting, and are less expensive to manufacture1 (see imiglucerase).
References
References
- Deegan PB, Cox TM (2012). "Imiglucerase in the treatment of Gaucher disease: a history and perspective". Drug Design, Development and Therapy. 6: 81–106. doi:10.2147/DDDT.S14395. PMC 3340106. PMID 22563238.
- World Health Organization. Regulatory Matters WHO Drug Information 5:3 1991. p 123
- Aetna. Last reviewed 8 August 2014 Clinical Policy Bulletin Number: 0442: Enzyme-replacement Therapy for Lysosomal Storage Disorders
- FDA Prescription and Over-the-Counter Drug Product List. 32ND Edition Cumulative Supplement Number 3: March 2012. Additions/Deletions for Prescription Drug Product List